UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/590,817	06/29/2007	Nawal Hijjawi	28594/42303	1154	
	7590 03/08/201 GERSTEIN & BORUN		EXAMINER		
233 SOUTH W	ACKER DRIVE	AFREMOVA, VERA			
6300 SEARS T CHICAGO, IL	_		ART UNIT PAPER NUMBER		
			1657		
			MAIL DATE	DELIVERY MODE	
			03/08/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
	Office Action Commons	10/590,817	HIJJAWI ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Vera Afremova	1657			
Period fo	The MAILING DATE of this communication appr Reply	opears on the cover sheet with the o	orrespondence address			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REP CHEVER IS LONGER, FROM THE MAILING I nsions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. o period for reply is specified above, the maximum statutory perior re to reply within the set or extended period for reply will, by statu- reply received by the Office later than three months after the mail ed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO .136(a). In no event, however, may a reply be tind d will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. mely filed the mailing date of this communicatio (35 U.S.C. § 133).			
Status	,					
_	Responsive to communication(s) filed on 29.	Juno 2007				
2a)□		is action is non-final.				
3)□	-					
٥)ا	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
	·	Ex parte Quayle, 1000 0.5. 11, 4	50 O. G . 210.			
Disposit	ion of Claims					
4)🛛	Claim(s) 1-40 is/are pending in the application	n.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.					
6)□	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)🛛	Claim(s) <u>1-40</u> are subject to restriction and/or	r election requirement.				
Applicat	ion Papers					
9)	The specification is objected to by the Examir	ner.				
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
, <u>—</u>	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11)	11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
	under 35 U.S.C. § 119					
12)	Acknowledgment is made of a claim for foreig	un priority under 35 U.S.C. § 119/a)-(d) or (f)			
	☐ All b)☐ Some * c)☐ None of:		, (=, =, (-,-			
/	1.☐ Certified copies of the priority docume	nts have been received				
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage					
	application from the International Bureau (PCT Rule 17.2(a)).					
* 6	* See the attached detailed Office action for a list of the certified copies not received.					
`						
Attachme -	t(a)					
Attachmen 1) Notice	t(s) ee of References Cited (PTO-892)	4) Interview Summary	, (PTO-413)			
	e of Draftsperson's Patent Drawing Review (PTO-948)	— Paper No(s)/Mail D				
3) Infor	mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal F 6) Other:	Patent Application			

DETAILED ACTION

Claims 1-40 (preliminary amendment 8/25/2006) are pending and subject to restriction requirement.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, 7-12 and 14, drawn to a first method of using a first cell free medium product for culturing Cryptosporidium to a second lifecycle stage.

Group II, claim(s) 5, drawn to a second method of using a first cell free medium product for culturing Cryptosporidium to complete its lifecycle.

Group III, claim(s) 6, drawn to a third method of using a first cell free medium product for culturing Cryptosporidium to increase biomass.

Group IV, claim(s) 13, drawn to a fourth method of using a first cell free medium product for culturing Cryptosporidium to harvest oocytes.

Group V, claim(s) 15-20, drawn to a first product that is a cell free culture medium comprising buffer, inorganic salts, amino acids, vitamins, etc.

Group VI, claim(s) 21-23, drawn to a fifth method of using a first cell free medium product for preparing an immonogenic preparation with Cryptosporidium antigen.

Group VII, claim(s) 24-29, drawn to a second product that is a therapeutic composition with effective amount of Cryptosporidium.

Group VIII, claim(s) 30, drawn to a first method of using a second product such as a therapeutic composition with effective amount of Cryptosporidium for treating Cryptosporidium infection.

Group IX, claim(s) 31 and 34-40, drawn to a first method for detecting Cryptosporidium in a sample.

Group X, claim(s) 32 drawn to a second method for detecting Cryptosporidium in a sample.

Group XI, claim(s) 33, drawn to a third method for detecting Cryptosporidium in a sample.

The inventions listed as Groups I-XI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

This application contains claims drawn to more than one of permissible combinations of categories of inventions such as more than one product(s) and more than one process of use said products. Furthermore, a "special technical feature" (that defines a contribution which each of the claimed inventions, considered as a whole, makes over the prior art) is known in the prior art. For example: a first product as claimed such as that is a cell free culture medium comprising buffer, inorganic salts, amino acids, vitamins, etc. is a common chemically defined cell culture medium including DMEM, Hams' or RPMI. Further, a second product as claimed a therapeutic composition with effective amount of Cryptosporidium is also known in the prior art, for

example: US 2003/0235903 (Thompson et al) teaches a vaccine composition with effective amount of Cryptosporidium as intended for immunizing animals against Cryptosporidium infection. Thus, unity of inventions is lacking. See MPEP 1850. 37 CFR 1.475.

- 37 CFR 1.475. Unity of invention before the International Searching Authority, the International Preliminary Examining Authority and during the national stage.
- (a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- (c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.
- (d) If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) and § 1.476(c).
- (e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (571) 272-0914. The examiner can normally be reached from Monday to Friday from 9.30 am to 6.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber, can be reached at (571) 272-0925.

The fax phone number for the TC 1600 where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology center 1600, telephone number is (571) 272-1600.

Vera Afremova

March 2, 2010

/Vera Afremova/

Primary Examiner, Art Unit 1657